HomeMarket NewsStalwart Opportunities: 3 Top Dividend Growth Stocks for the Long Haul

Stalwart Opportunities: 3 Top Dividend Growth Stocks for the Long Haul

Actionable Trade Ideas

always free

Investing in the stock market can be akin to a high-speed rollercoaster ride or a smooth cruise across still waters, depending on your style. For those seeking a reliable, long-term investment to cushion the rocky road to retirement, the healthcare sector stands firm as a beacon of consistency amidst the unpredictable market fluctuations and trends.

Johnson & Johnson: The Pillar of Steady Growth

Embodying unwavering reliability, Johnson & Johnson (NYSE: JNJ) recently celebrated its 61st consecutive annual dividend increase. Despite not boasting the highest yield, the stock remains steady at a 3.1% yield. Over the past five years, J&J has boosted its dividend payout by an impressive 25%, demonstrating a commitment to rewarding loyal shareholders.

Following the successful spinoff of its consumer health division, Johnson & Johnson is now a focused powerhouse in medical technology and pharmaceuticals. With robust earnings growth, set at $9.92 per share in 2023, and an annualized dividend payout of $4.76 per share, J&J has ample room to continue rewarding investors generously.

A titan in the medical industry, with total revenue hitting $85.2 billion in 2023, Johnson & Johnson consistently leverages its strength and size to produce steady gains. Its recent move to acquire Shockwave Medical signifies a strategic expansion into the cardiovascular devices market, underscoring the company’s commitment to growth and innovation.

Medtronic: A Solid Player in Medical Technology

Medtronic (NYSE: MDT), a key player in medical technology, raised its dividend payout for the 46th consecutive year in May 2023. Offering a 3.3% yield at recent prices, Medtronic’s pace of dividend growth slowed to 38% over the past five years but shows signs of picking up steam in the near future.

Bouncing back from supply chain disruptions, Medtronic reported a 4.7% year-over-year sales growth during its latest fiscal quarter. The recent approval from the U.S. FDA for its transcatheter aortic valve replacement system spells potential for a significant boost in the cardiovascular segment sales. This approval marks a new chapter of growth for Medtronic in the medical technology space.

AbbVie: Navigating the Competitive Pharmaceuticals Arena

AbbVie (NYSE: ABBV), a pharmaceutical giant, offers a solid 3.5% yield at recent prices. Despite facing biosimilar competition impacting Humira sales, AbbVie remains resilient with a 288% increase in dividend payout since its spinoff from Abbott Laboratories in 2013.

With blockbuster drugs like Skyrizi and Rinvoq offsetting the decline in Humira’s sales, AbbVie displays a commitment to innovation and growth. The company’s robust product pipeline and strategic acquisitions position it well for future success, with management projecting high single-digit annual sales growth from 2024 to 2029.

In a world where market volatility and uncertainty reign supreme, these three stalwart companies stand as beacons of stability and growth in the healthcare industry. As the population ages and healthcare needs continue to rise, investing in these dependable dividend growth stocks could pave the way for a financially secure future.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.